FRAMINGHAM, Mass. and SYDNEY, Aug. 8, 2011 /PRNewswire/ —
HeartWare International, Inc. (NASDAQ:
HTWR; ASX: HIN), a leading innovator of less invasive,
miniaturized circulatory support technologies that are
revolutionizing the treatment of advanced heart failure, today
announced that CEO Doug Godshall is scheduled to make an investor
presentation at the Canaccord Genuity 31st Annual Growth Conference
at 9:00 a.m. U.S. Eastern Time on Thursday, August 11, 2011.
The conference is being held August 9-11, 2011 at The
InterContinental Hotel in Boston.
A live webcast of the Company’s presentation at the conference
will be available via a link provided at www.heartware.com. An
archived replay of the presentation will also be available shortly
after the presentation time for 90 days.
About HeartWare International
HeartWare International develops and manufactures miniaturized
implantable heart pumps, or ventricular assist devices, to treat
Class IIIB / IV patients suffering from advanced heart failure.
The HeartWare® Ventricular Assist System features the
HVAD® pump, a small full-output circulatory support device (up
to 10L/min flow) designed to be implanted next to the heart,
avoiding the abdominal surgery generally required to implant
competing devices. HeartWare has received CE Marking for the
HeartWare System in the European Union and TGA approval in
Australia. The device is currently the subject of United
States clinical trials for two indications: bridge-to-transplant
and destination therapy. For additional information, please
HeartWare International, Inc. is a member of the Russell
2000® and its securities are publicly traded on The NASDAQ
Stock Market and the Australian Securities Exchange.</